PURPOSE: Previous studies examining the association of body mass index (BMI) with risk of and survival from head and neck squamous cell carcinoma (HNSCC) have been inconsistent, although an inverse association has been noted for obesity and risk of HNSCC in several studies. Previous studies have not examined whether these associations differ by human papillomavirus (HPV) status. METHODS: We utilized the resources of a population-based case-control study of HNSCC from the greater Boston area (959 cases and 1,208 controls were eligible for this analysis). Anthropometric history was collected through personal interviews, and HPV status was assessed using serology. We analyzed the association between BMI (assessed 5 years prior to disease incidence) and disease risk and survival using logistic regression and Cox proportional hazards regression, respectively. RESULTS: After adjusting for known risk factors, the association between obesity and overall risk of HNSCC was not significant (OR 0.79, 95 % CI 0.60-1.04). However, obesity (BMI ≥30 kg/m(2)) was inversely associated with HNSCC risk among HPV-seronegative cases (OR 0.48, 95 % CI 0.32-0.70), but not among HPV-seropositive cases (OR 0.91, 95 % CI 0.68-1.21). BMI was not associated with survival overall or by HPV status. However, being overweight (BMI 25-29.9 kg/m(2)) was associated with longer survival among HPV-seropositive smokers (HR 0.48, 95 % CI 0.31-0.74). CONCLUSIONS: Our findings are consistent with previous observations that obesity is inversely associated with the risk of HNSCC; however, this association appears to be confined to HPV-seronegative cases. Overall, obesity was not associated with HNSCC survival overall or by HPV status. IMPACT: Obesity is associated with risk of non-HPV HNSCC, but not HPV HNSCC.
PURPOSE: Previous studies examining the association of body mass index (BMI) with risk of and survival from head and neck squamous cell carcinoma (HNSCC) have been inconsistent, although an inverse association has been noted for obesity and risk of HNSCC in several studies. Previous studies have not examined whether these associations differ by human papillomavirus (HPV) status. METHODS: We utilized the resources of a population-based case-control study of HNSCC from the greater Boston area (959 cases and 1,208 controls were eligible for this analysis). Anthropometric history was collected through personal interviews, and HPV status was assessed using serology. We analyzed the association between BMI (assessed 5 years prior to disease incidence) and disease risk and survival using logistic regression and Cox proportional hazards regression, respectively. RESULTS: After adjusting for known risk factors, the association between obesity and overall risk of HNSCC was not significant (OR 0.79, 95 % CI 0.60-1.04). However, obesity (BMI ≥30 kg/m(2)) was inversely associated with HNSCC risk among HPV-seronegative cases (OR 0.48, 95 % CI 0.32-0.70), but not among HPV-seropositive cases (OR 0.91, 95 % CI 0.68-1.21). BMI was not associated with survival overall or by HPV status. However, being overweight (BMI 25-29.9 kg/m(2)) was associated with longer survival among HPV-seropositive smokers (HR 0.48, 95 % CI 0.31-0.74). CONCLUSIONS: Our findings are consistent with previous observations that obesity is inversely associated with the risk of HNSCC; however, this association appears to be confined to HPV-seronegative cases. Overall, obesity was not associated with HNSCC survival overall or by HPV status. IMPACT: Obesity is associated with risk of non-HPV HNSCC, but not HPV HNSCC.
Authors: W Garavello; G Randi; C Bosetti; L Dal Maso; E Negri; L Barzan; S Franceschi; C La Vecchia Journal: Ann Oncol Date: 2006-07-27 Impact factor: 32.976
Authors: Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita Journal: Clin Chem Date: 2005-08-11 Impact factor: 8.327
Authors: Aimée R Kreimer; Giorgia Randi; Rolando Herrero; Xavier Castellsagué; Carlo La Vecchia; Silvia Franceschi Journal: Int J Cancer Date: 2006-05-01 Impact factor: 7.396
Authors: C Sloane Furniss; Michael D McClean; Judith F Smith; Janine Bryan; Heather H Nelson; Edwards S Peters; Marshall R Posner; John R Clark; Ellen A Eisen; Karl T Kelsey Journal: Int J Cancer Date: 2007-06-01 Impact factor: 7.396
Authors: Rolando Herrero; Xavier Castellsagué; Michael Pawlita; Jolanta Lissowska; Frank Kee; Prabda Balaram; Thangarajan Rajkumar; Hema Sridhar; Barbara Rose; Javier Pintos; Leticia Fernández; Ali Idris; María José Sánchez; Adoración Nieto; Renato Talamini; Alessandra Tavani; F Xavier Bosch; Ulrich Reidel; Peter J F Snijders; Chris J L M Meijer; Raphael Viscidi; Nubia Muñoz; Silvia Franceschi Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: William G Albergotti; Kara S Davis; Shira Abberbock; Julie E Bauman; James Ohr; David A Clump; Dwight E Heron; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Robert L Ferris Journal: Oral Oncol Date: 2016-07-07 Impact factor: 5.337
Authors: Anshu Khanna; Eric M Sturgis; Kristina R Dahlstrom; Li Xu; Qingyi Wei; Guojun Li; Neil D Gross Journal: Am J Cancer Res Date: 2021-05-15 Impact factor: 6.166